Explanipedia

Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure Open

Daan C H Ceelen, Jozine M. ter Maaten, Geert H.D. Voordes, Gad Cotter, Beth A. Davison , et al. · 2025

Aims Residual congestion (RC) is common at discharge after acute decompensated heart failure (ADHF) and is associated with early mortality and rehospitalization. The prognostic value of distinct RC phenotypes (i.e. intravascular and tissue…

HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America Open

Gregg C. Fonarow, Faraz S. Ahmad, Tariq Ali Ahmad, Nancy M. Albert, Kevin Alexander , et al. · 2025

Impact of Mild and Moderate Aortic Stenosis in Acute Heart Failure: Insights From RELAX-AHF-2 Open

Constantijn S. Venema, Marco Metra, Laura Staal, Iris E. Beldhuis, Gad Cotter , et al. · 2025

The presence of mild or moderate aortic stenosis reflects an increased risk profile in patients with acute heart failure, but it is not an independent predictor of poor clinical outcomes.

Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial Open

Misato Chimura, Kieran F. Docherty, Pardeep S. Jhund, Mingming Yang, Ryohei Ono , et al. · 2025

Background and Aims The frequency and prognostic significance of abnormalities in serum magnesium concentrations have not been described in a contemporary HF population. The authors evaluated the prognostic significance of magnesium concen…

Late diagnosis in cancer sparks outrage—so why not heart failure? Open

Antoni Bayés‐Genís, Lisa Anderson, E J Harding, Marco Metra, John R. Teerlink , et al. · 2025

Stroke in Heart Failure With Reduced Ejection Fraction Open

Guglielmo Gallone, Federica Savoca, D Miccoli, Michael Böhm, Gaetano Maria De Ferrari , et al. · 2025

Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis Open

João Pedro Ferreira, Francisco Vasques‐Nóvoa, Christiane E. Angermann, Jan Biegus, Sean P. Collins , et al. · 2025

Aims Empagliflozin improves outcomes in acute heart failure (AHF). Patients with AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is effective and safe in patients with AHF and low BP is currently unknown. The aim…

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial Open

Peter Carson, John R. Teerlink, Michel Komajda, Inder S. Anand, Milton Packer , et al. · 2025

Investigator adjudication is an alternative to a CEC with similar accuracy and faster event accumulation in HFpEF. The use of granular (SCTI) criteria did not improve trial performance. Our data suggest that a broader definition of an HHF …

End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2) Open

Adriaan A. Voors, Marco Metra, Douwe Postmus, Barry Greenberg, Gad Cotter , et al. · 2024

Aims Serelaxin is recombinant human relaxin‐2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy. In the RELAX‐AHF trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage. In RELAX‐A…

The 25in25 initiative: A novel transformative project to reduce mortality due to heart failure by 25% in the next 25 years Open

Henry Oluwasefunmi Savage, Kyle McBeath, Janine Hogan, Lynn Mackay-Thomas, Lisa Anderson , et al. · 2024

No abstract available.

Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE Open

João Pedro Ferreira, Jon Blatchford, John R. Teerlink, Mikhail Kosiborod, Christiane E. Angermann , et al. · 2024

Aims Patients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days after hospital admission. The timing of treatment initiation may influence the e…

Distinct Comorbidity Clusters in Patients With Acute Heart Failure Open

Karla Arevalo Gomez, Jasper Tromp, Sylwia M. Figarska, Iris E. Beldhuis, Gad Cotter , et al. · 2024

Comorbidities naturally clustered into 5 mutually exclusive groups in RELAX-AHF-2, showing variations in clinical outcomes. These data emphasize that the specific combination of comorbidities can influence adverse outcomes and treatment re…

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial Open

Jasper Tromp, Mikhail Kosiborod, Christiane E. Angermann, Sean P. Collins, John R. Teerlink , et al. · 2024

Aim The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium–glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical out…

Clinical Trial Inclusion and Impact on Early Adoption of Medical Innovation in Diverse Populations Open

Philip B. Adamson, Melvin Echols, Ersilia M. DeFilippis, Alanna A. Morris, Mosi K. Bennett , et al. · 2024

Demographics of Centers for Medicare and Medicaid Services beneficiaries hospitalized with HF vary regionally and by age, which should be considered when defining "adequate" representation in clinical studies. Enrollment diversity in clini…

Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure Open

Joshua Newman, Eileen O’Meara, Michael Böhm, Gianluigi Savarese, Patricia R. Kelly , et al. · 2024

Effective medications can work only in patients who take them: Implications for post‐acute heart failure care Open

Gad Cotter, Beth A. Davison, Kirkwood F. Adams, Andrew P. Ambrosy, L. S. Atabaeva , et al. · 2023

Acute heart failure (AHF) remains a predominant cause of hospitalization, especially among individuals aged 65 years or older, contributing to millions of hospitalizations per year globally.1, 2 Despite advances in therapeutic approach, AH…

Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies Open

Anuradha Lala, Carine Hamo, Biykem Bozkurt, Mona Fiuzat, Vanessa Blumer , et al. · 2023

Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS‐986231) Open

Pierpaolo Pellicori, John G.F. Cleland, Maria Borentain, Jörg Täubel, Fraser J Graham , et al. · 2023

Aim To investigate the effects of Cimlanod, a nitroxyl donor with vasodilator properties, on water and salt excretion after an administration of an intravenos bolus of furosemide. Methods and results In this randomized, double‐blind, mecha…

Acute Heart Failure Is a Malignant Process: But We Can Induce Remission Open

Gad Cotter, Beth A. Davison, Carolyn S.P. Lam, Marco Metra, Piotr Ponikowski , et al. · 2023

Acute heart failure is a common and increasingly prevalent condition, affecting >10 million people annually. For those patients who survive to discharge, early readmissions and death rates are >30% everywhere on the planet, making it a mal…

The HFSA Advanced Heart Failure and Transplant Cardiology Fellowship Consensus Conference Open

Mark H. Drazner, Amrut V. Ambardekar, Kathryn Berlacher, Vanessa Blumer, Safia Chatur , et al. · 2023

Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America Open

Biykem Bozkurt, Tariq Ahmad, Kevin Alexander, William L. Baker, Kelly Bosak , et al. · 2023

The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF Open

Kieran F. Docherty, John J.V. McMurray, Rafael Díaz, G. Michael Felker, Marco Metra , et al. · 2023

Hospitalized patients with HF with reduced ejection fraction had a higher rate of the primary outcome than outpatients. Omecamtiv mecarbil decreased the risk of the primary outcome both when initiated in hospitalized patients and in outpat…

Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE Open

João Pedro Ferreira, Jon Blatchford, John R. Teerlink, Mikhail Kosiborod, Christiane E. Angermann , et al. · 2023

Aims In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empaglif…

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure Open

Iris E. Beldhuis, Kevin Damman, Peter S. Pang, Barry Greenberg, Beth A. Davison , et al. · 2023

Aims Heart failure (HF) guidelines recommend initiation and optimization of guideline‐directed medical therapy, including mineralocorticoid receptor antagonists (MRAs), before hospital discharge. However, scientific evidence for this recom…

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension Open

Stefan D. Anker, Muhammad Usman, Markus S. Anker, Javed Butler, Michael Böhm , et al. · 2023

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation…

The win ratio method in heart failure trials: lessons learnt from EMPULSE Open

Stuart Pocock, João Pedro Ferreira, Timothy Collier, Christiane E. Angermann, Jan Biegus , et al. · 2023

Aims The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo using the stratified win ratio approach in 530 patients with acute heart failure (HF) after initial stabilization. We aim to elucidate how this method wo…

Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX‐AHF‐2 trial Open

Matteo Pagnesi, Marianna Adamo, Jozine M. ter Maaten, Iris E. Beldhuis, Gad Cotter , et al. · 2023

Aims The impact of mitral regurgitation (MR) in patients hospitalized for acute heart failure (AHF) is not well established. We assessed the role of MR in patients enrolled in the Relaxin in Acute Heart Failure 2 (RELAX‐AHF‐2) trial. Metho…

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction Open

David E. Lanfear, Joyce Njoroge, Kirkwood F. Adams, Inder S. Anand, James C. Fang , et al. · 2023

GALACTIC-HF enrolled more Black patients than other recent HF trials. Black patients treated with omecamtiv mecarbil had similar benefit and safety compared with White counterparts.

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial Open

Peter E. Carson, John R. Teerlink, Michel Komajda, Inder S. Anand, Stefan D. Anker , et al. · 2023

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure Open

Iris E. Beldhuis, Jozine M. ter Maaten, Sylwia M. Figarska, Kevin Damman, Peter S. Pang , et al. · 2023

John R. Teerlink YOU? Author Swipe